EpiBiologics closed a $107 million Series B to advance its bispecific antibody pipeline in oncology and immunology.
- Amount
- $107M
- Stage
- Series B
- Announced
- 8 January 2026
- Checked
- Amount and date checked against the press source
EpiBiologics
Raised $107M in a Series B round, announced 8 January 2026.
Round
Company
Develops bispecific antibodies that selectively degrade extracellular protein targets in oncology and immunology.
- Sector
- Health
- Website
- epibiologics.com ↗
Sources and links
Just raised?
MediaBoost gets your round in front of the press, future hires and your next investors.
Announce your round with MediaBoost